Login Register Cart 0
Research Article

Evaluation of Fluctuations of BRAF Gene Expression and its Polymorphism at rs1267623 in Colorectal Cancer

In Press, (this is not the final "Version of Record"). Available online 12 July, 2024
Author(s): Seyedeh Elham Norollahi, Kosar Babaei, Sogand Vahidi, Seyed Javad Hosseini Motaz, Mahmoud Kalani Tarbeghan, Mostafa Khaleghipour, Elaheh Asghari Gharakhyli, Seyed Reza Mirhafez* and Ali Akbar Samadani*
Published on: 12 July, 2024

DOI: 10.2174/0122115366286360240625095932

Price: $95

Abstract

Background: Molecular markers in Colorectal Cancer (CRC) are needed for more ac-curate classification and personalized treatment. In this way, we investigated the effects of the BRAF gene on clinical outcomes of its expression fluctuations and its polymorphism at rs1267623 in CRC.

Methods: In this study, 36.36 percent of patients with CRC were women, and 63.63 percent were men. After the pathology department confirmed the tumor of the samples, the stage and grade of the tumor were determined according to the TNM system. Real-time PCR was used to check the expression of the BRAF gene in tumor and non-tumor tissues, and its polymorphism in rs1267623 was also checked using the Tetra-ARMs PCR technique.

Results: The expression of BRAF in tumor tissues was significantly higher than in non-tumoral tissues (P = 0.001), indicating an upregulation of BRAF gene expression in tumoral tissues. The user's text is empty. Furthermore, there was a significant correlation between BRAF expression and tumor stage (P = 0.001), as well as tumor grade (P = 0.003). However, no significant link was found between lymph node metastasis and distant metastasis of BRAF gene expression (P = 0.3). Additionally, no mutation was detected in the investigation of rs1267623 polymorphism.

Conclusion: The BRAF gene was upregulated in tumoral tissues. Remarkably, no mutation was found in the rs1267623 polymorphism. As a result, this gene can be used as a biomarker in the diagnosis and treatment of CRC.

[1]
Zhang J, Lai W, Li Q, et al. A novel oncolytic adenovirus targeting Wnt signaling effectively inhibits cancer-stem like cell growth via metastasis, apoptosis and autophagy in HCC models. Biochem Biophys Res Commun 2017; 491(2): 469-77.
[http://dx.doi.org/10.1016/j.bbrc.2017.07.041] [PMID: 28698142]
[2]
Rassy E, Parent P, Lefort F, Boussios S, Baciarello G, Pavlidis N. New rising entities in cancer of unknown primary: Is there a real therapeutic benefit? Crit Rev Oncol Hematol 2020; 147: 102882.
[http://dx.doi.org/10.1016/j.critrevonc.2020.102882] [PMID: 32106012]
[3]
Hui D, Kim SH, Roquemore J, Dev R, Chisholm G, Bruera E. Impact of timing and setting of palliative care referral on quality of end‐of‐life care in cancer patients. Cancer 2014; 120(11): 1743-9.
[http://dx.doi.org/10.1002/cncr.28628] [PMID: 24967463]
[4]
Atlas SJ, Zai AH, Ashburner JM, et al. Non-visit-based cancer screening using a novel population management system. J Am Board Fam Med 2014; 27(4): 474-85.
[http://dx.doi.org/10.3122/jabfm.2014.04.130319] [PMID: 25002002]
[5]
Chen J, Guo F, Shi X, et al. BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients. BMC Cancer 2014; 14(1): 802.
[http://dx.doi.org/10.1186/1471-2407-14-802] [PMID: 25367198]
[6]
Marranci A, Jiang Z, Vitiello M, et al. The landscape of BRAF transcript and protein variants in human cancer. Mol Cancer 2017; 16(1): 85.
[http://dx.doi.org/10.1186/s12943-017-0645-4] [PMID: 28454577]
[7]
Grothey A, Fakih M, Tabernero J. Management of BRAF-mutant metastatic colorectal cancer: A review of treatment options and evidence-based guidelines. Ann Oncol 2021; 32(8): 959-67.
[http://dx.doi.org/10.1016/j.annonc.2021.03.206] [PMID: 33836264]
[8]
Luu L-J, Price J. BRAF mutation and its importance in colorectal cancer. Advances in the Molecular Understanding of Colorectal Cancer. London: InTechOpen 2019; pp. 1-18.
[http://dx.doi.org/10.5772/intechopen.82571]
[9]
Barras D. BRAF mutation in colorectal cancer: An update. Biomark Cancer 2015; 7 (Suppl. 1): 9-12.
[10]
Adeleke S, Haslam A, Choy A, et al. Microsatellite instability testing in colorectal patients with Lynch syndrome: Lessons learned from a case report and how to avoid such pitfalls. Per Med 2022; 19(4): 277-86.
[http://dx.doi.org/10.2217/pme-2021-0128] [PMID: 35708161]
[11]
Martinetti D, Costanzo R, Kadare S, et al. KRAS and BRAF mutational status in colon cancer from Albanian patients. Diagn Pathol 2014; 9(1): 187.
[http://dx.doi.org/10.1186/s13000-014-0187-7] [PMID: 25267307]
[12]
Clarke CN, Kopetz ES. BRAF mutant colorectal cancer as a distinct subset of colorectal cancer: Clinical characteristics, clinical behavior, and response to targeted therapies. J Gastrointest Oncol 2015; 6(6): 660-7.
[PMID: 26697199]
[13]
Fakih MG. Metastatic colorectal cancer: Current state and future directions. J Clin Oncol 2015; 33(16): 1809-24.
[http://dx.doi.org/10.1200/JCO.2014.59.7633] [PMID: 25918280]
[14]
Sinicrope FA, Mahoney MR, Smyrk TC, et al. Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy. J Clin Oncol 2013; 31(29): 3664-72.
[http://dx.doi.org/10.1200/JCO.2013.48.9591] [PMID: 24019539]
[15]
Barras D, Missiaglia E, Wirapati P, et al. BRAF V600E mutant colorectal cancer subtypes based on gene expression. Clin Cancer Res 2017; 23(1): 104-15.
[http://dx.doi.org/10.1158/1078-0432.CCR-16-0140] [PMID: 27354468]
[16]
Price TJ, Hardingham JE, Lee CK, et al. Impact of KRAS and BRAF gene mutation status on outcomes from the phase III AGITG MAX trial of capecitabine alone or in combination with bevacizumab and mitomycin in advanced colorectal cancer. J Clin Oncol 2011; 29(19): 2675-82.
[http://dx.doi.org/10.1200/JCO.2010.34.5520] [PMID: 21646616]
[17]
Venderbosch S, Nagtegaal ID, Maughan TS, et al. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: A pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin Cancer Res 2014; 20(20): 5322-30.
[http://dx.doi.org/10.1158/1078-0432.CCR-14-0332] [PMID: 25139339]
[18]
Sinicrope FA, Shi Q, Smyrk TC, et al. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes. Gastroenterology 2015; 148(1): 88-99.
[http://dx.doi.org/10.1053/j.gastro.2014.09.041] [PMID: 25305506]
[19]
Hirschi B, Gallmeier E, Ziesch A, Marschall M, Kolligs FT. Genetic targeting of B-RafV600E affects survival and proliferation and identifies selective agents against BRAF-mutant colorectal cancer cells. Mol Cancer 2014; 13(1): 122.
[http://dx.doi.org/10.1186/1476-4598-13-122] [PMID: 24885690]
[20]
Herr R, Köhler M, Andrlová H, et al. B-Raf inhibitors induce epithelial differentiation in BRAF-mutant colorectal cancer cells. Cancer Res 2015; 75(1): 216-29.
[http://dx.doi.org/10.1158/0008-5472.CAN-13-3686] [PMID: 25381152]
[21]
Saridaki Z, Souglakos J, Georgoulias V. Prognostic and predictive significance of MSI in stages II/III colon cancer. World J Gastroenterol 2014; 20(22): 6809-14.
[http://dx.doi.org/10.3748/wjg.v20.i22.6809] [PMID: 24944470]
[22]
Osseis M, Nehmeh WA, Rassy N, et al. Surgery for T4 colorectal cancer in older patients: Determinants of outcomes. J Pers Med 2022; 12(9): 1534.
[http://dx.doi.org/10.3390/jpm12091534] [PMID: 36143319]
[23]
Fan JZ, Wang GF, Cheng XB, et al. Relationship between mismatch repair protein, RAS, BRAF, PIK3CA gene expression and clinicopathological characteristics in elderly colorectal cancer patients. World J Clin Cases 2021; 9(11): 2458-68.
[http://dx.doi.org/10.12998/wjcc.v9.i11.2458] [PMID: 33889611]
[24]
Lochhead P, Kuchiba A, Imamura Y, et al. Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst 2013; 105(15): 1151-6.
[http://dx.doi.org/10.1093/jnci/djt173] [PMID: 23878352]
[25]
Boussios S, Ozturk M, Moschetta M, et al. The developing story of predictive biomarkers in colorectal cancer. J Pers Med 2019; 9(1): 12.
[http://dx.doi.org/10.3390/jpm9010012] [PMID: 30736475]
[26]
Sinicrope FA, Shi Q, Allegra CJ, et al. Association of DNA mismatch repair and mutations in BRAF and KRAS with survival after recurrence in stage III colon cancers: A secondary analysis of 2 randomized clinical trials. JAMA Oncol 2017; 3(4): 472-80.
[http://dx.doi.org/10.1001/jamaoncol.2016.5469] [PMID: 28006055]
[27]
Piccioli P, Serra M, Gismondi V, et al. Multiplex tetra-primer amplification refractory mutation system PCR to detect 6 common germline mutations of the MUTYH gene associated with polyposis and colorectal cancer. Clin Chem 2006; 52(4): 739-43.
[http://dx.doi.org/10.1373/clinchem.2005.060137] [PMID: 16455870]
[28]
Won DD, Lee JI, Lee IK, Oh ST, Jung ES, Lee SH. The prognostic significance of KRAS and BRAF mutation status in Korean colorectal cancer patients. BMC Cancer 2017; 17(1): 403.
[http://dx.doi.org/10.1186/s12885-017-3381-7] [PMID: 28583095]
[29]
Nakaji Y, Oki E, Nakanishi R, et al. Prognostic value of BRAF V600E mutation and microsatellite instability in Japanese patients with sporadic colorectal cancer. J Cancer Res Clin Oncol 2017; 143(1): 151-60.
[http://dx.doi.org/10.1007/s00432-016-2275-4] [PMID: 27672042]
[30]
Fariña-Sarasqueta A, van Lijnschoten G, Moerland E, et al. The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients. Ann Oncol 2010; 21(12): 2396-402.
[http://dx.doi.org/10.1093/annonc/mdq258] [PMID: 20501503]
[31]
Li Y, Li W. BRAF mutation is associated with poor clinicopathological outcomes in colorectal cancer: A meta-analysis. Saudi J Gastroenterol 2017; 23(3): 144.
[32]
Yang M, Schell MJ, Yeatman TJ. Abstract 3170: BRAF expression is associated with poor survival in colorectal cancers independent of BRAF (V600E) mutation. Cancer Res 2019; 79(13_Supplement)(Suppl.): 3170.
[http://dx.doi.org/10.1158/1538-7445.AM2019-3170] [PMID: 31048498]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy